Enterprise Web Briefing on Vaccine-Induced Sero-Positivity/Reactivity Consultation
Thursday, 2 May at 11:00 a.m. EDT
Please join us on Thursday, 2 May at 11:00 a.m. EDT for a web briefing on the Global HIV Vaccine Enterprise's latest Timely Topics
in HIV Vaccines consultation on Vaccine Induced Sero-Positivity/Reactivity (VISP/R). The Enterprise, IAVI and NIAID will present highlights
from the recent consultation, including preliminary recommendations to develop a coordinated field-wide approach to VISP/R.
HIV VISP/R occurs when a trial participant develops antibodies to the HIV components in the vaccine candidate and therefore
tests positive on some diagnostic HIV tests, which look for the presence of antibodies as a sign of infection. Given that HIV vaccine
candidates are becoming more complex and are more likely to elicit robust and durable antibody responses, HIV vaccine trial
participants will increasingly encounter VISP/R.
Preparation for large-scale efficacy trials further adds to this issue, which is why the Enterprise and partners convened
vaccine researchers, developers of commercial tests, normative and regulatory agencies and community representatives to help formulate
and develop plans to implement best practices for short- and long-term support of trial volunteers.
This webinar will feature presentations from Pat Fast (IAVI) and Mary Allen (NIAID) who will update on the issues raised during
the consultation and possible approaches to addressing VISP/R. Anyone with an interest in HIV vaccine clinical trials design, product
development, antibody testing or participant issues should plan to attend. There will be ample time for questions and comments.
Register for the Webinar
To access the webinar, please register here: https://cc.readytalk.com/r/9t7493oqncj3 . If you are
unable to attend, we will post a link to the recording of the webinar on our web site, http://www.vaccineenterprise.org/content/timely-topic-VISP .
Background on the consultation, including presentations shared with participants, can be found on our web
site, http://www.vaccineenterprise.org/content/timely-topic-VISP . This consultation
was organized by the Enterprise together with the International AIDS Vaccine Initiative (IAVI) , National Institute of Allergy and Infectious Diseases (NIAID/NIH), U.S. Military HIV Research
Program, U.S. Blood Systems Research Institute, U.S. Food and Drug Administration (FDA), Zambia National Blood Transfusion Service and the World Health Organization (WHO).
NOW AVAILABLE: HIV Prevention Trials in Infants Meeting Report
Last month, the Enterprise, the Elizabeth Glaser Pediatric AIDS Foundation, IMPAACT Network and the Vaccine Research Center convened a consultation in Entebbe, Uganda to help develop
recommendations for the design and conduct of current and future HIV prevention trials in infants born to HIV-positive mothers. The report
from the meeting is now available, here .
About Timely Topics in HIV Vaccines
Timely Topics in HIV Vaccines is a new strategy series to identify and respond to unresolved and emerging priority issues to help accelerate HIV vaccine
R&D. Through an open call for proposals, the Enterprise aims to identify the most strategic needs of the field and will sponsor
think tanks, meetings, forums and develop other products to tackle these issues. ###
About the Global HIV Vaccine Enterprise
The Global HIV Vaccine Enterprise is a unique alliance of independent research organizations, funders and advocates dedicated to
accelerating the development of safe and effective HIV vaccines. Enterprise stakeholders are the global leaders in HIV vaccine
research: the African AIDS Vaccine Partnership, the Global Advocacy for HIV Prevention (AVAC), AIDS Vaccine for Asia Network,
The Bill & Melinda Gates Foundation, European Commission, GlaxoSmithKline, Government of Canada, the International AIDS
Vaccine Initiative (IAVI), the Medical Research Council, Merck, National Agency for research on AIDS and Viral Hepatitis
in France (ANRS), Novartis, sanofi pasteur, the U.S. National Institutes of Health, U.S. Agency for International
Development (USAID), U.S. Military HIV Research Program, Joint United Nations Programme on HIV/AIDS (UNAIDS),
Wellcome Trust and World Health Organization.
Contacts
Jennifer Brunet
+1 (212) 461-3693
jbrunet@vaccineenterprise.org
"Reproduced with permission - Global HIV Vaccine Enterprise"
Global HIV Vaccine Enterprise
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
